Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Boosted by Dillon & Associates Inc.

Dillon & Associates Inc. lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 6.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 13,525 shares of the biopharmaceutical company's stock after purchasing an additional 878 shares during the quarter. Regeneron Pharmaceuticals comprises approximately 2.0% of Dillon & Associates Inc.'s portfolio, making the stock its 15th largest holding. Dillon & Associates Inc.'s holdings in Regeneron Pharmaceuticals were worth $14,215,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of REGN. Vanguard Group Inc. lifted its position in Regeneron Pharmaceuticals by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company's stock valued at $8,595,268,000 after acquiring an additional 91,956 shares during the period. Capital International Investors grew its stake in shares of Regeneron Pharmaceuticals by 7.3% in the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company's stock worth $3,011,640,000 after acquiring an additional 213,038 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Regeneron Pharmaceuticals by 25.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company's stock valued at $868,757,000 after purchasing an additional 184,561 shares during the last quarter. International Assets Investment Management LLC boosted its holdings in Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company's stock worth $926,078,000 after purchasing an additional 879,916 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its holdings in Regeneron Pharmaceuticals by 12.4% in the second quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company's stock worth $567,864,000 after purchasing an additional 59,769 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Down 1.1 %

Shares of REGN stock traded down $9.34 on Wednesday, reaching $811.66. 276,485 shares of the stock were exchanged, compared to its average volume of 522,669. The company has a market capitalization of $89.19 billion, a price-to-earnings ratio of 20.09, a PEG ratio of 3.10 and a beta of 0.15. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The business's 50 day moving average price is $1,007.57 and its 200 day moving average price is $1,037.30. Regeneron Pharmaceuticals, Inc. has a twelve month low of $784.96 and a twelve month high of $1,211.20.

Insider Transactions at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares of the company's stock, valued at approximately $18,447,575.65. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 7.48% of the company's stock.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of research reports. JPMorgan Chase & Co. reduced their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an "overweight" rating for the company in a research report on Thursday, October 24th. Cantor Fitzgerald reiterated a "neutral" rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Royal Bank of Canada reduced their price objective on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an "outperform" rating for the company in a research note on Friday, November 1st. StockNews.com cut Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Monday, November 4th. Finally, Wells Fargo & Company cut their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an "overweight" rating for the company in a research note on Tuesday, October 22nd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $1,107.25.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.